NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
77.64 USD   +2.67%
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : NovoCure Limited Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 07:30 AM

01/11/2022 | 07:30am EDT
Good morning, and welcome to day 2 of the 40th Annual JPMorgan Healthcare Conference. My name is Gavin Scott, and I'm a biotech analyst here at JPMorgan. This morning, it's my pleasure to introduce...


© S&P Capital IQ 2022
All news about NOVOCURE LIMITED
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
AQ
07/28NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended J..
CI
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -99,2x
Yield 2022 -
Capitalization 8 132 M 8 132 M -
EV / Sales 2022 15,1x
EV / Sales 2023 14,2x
Nbr of Employees 1 167
Free-Float 86,8%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 77,64 $
Average target price 94,25 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED3.41%8 132
MASIMO CORPORATION-47.59%8 518
SHOCKWAVE MEDICAL, INC.25.13%7 987
PENUMBRA, INC.-41.94%6 321
GETINGE AB-44.19%5 869
IRAY TECHNOLOGY COMPANY LIMITED1.23%5 403